Collegium Pharmaceutical Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Collegium Pharmaceutical Inc 's ROA in the second quarter of 2026?
Collegium Pharmaceutical Inc achieved a return on average assets (ROA) of 2.73 % in its second quarter of 2026, this is above COLL's average return on assets of -5.22%.
Collegium Pharmaceutical Inc assets over the 12 months ending in its second quarter of 2026 are valued at $1,758 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 182 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 1256, from total ROA ranking in the first quarter of 2026 at 1633.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	33.12 %	1.4 %	-0.66 %	-1.61 %	51.27 %
Y / Y Net Income Change	-	499.75 %	35.31 %	237.51 %	-38.88 %
Net Income (TTM) in million	48	75	63	58	36
Return On Assets (TTM)	2.73 %	4.61 %	3.88 %	3.6 %	2.23 %
COLL's Total Ranking	# 1256	# 1633	# 1459	# 1772	# 1608
Total Assets (TTM) in million	2,116	1,652	1,657	1,606	1,590
Seq. Total Assets Change	28.09 %	-0.29 %	3.16 %	1.04 %	-2.43 %
Seq. Net Income Change	-	-14.54 %	-46.16 %	162.93 %	395.78 %

COLL's 5 Years Annual ROA >> Back to COLL Management Effectiveness >> Compare COLL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 66
Sector	# 183
Overall	# 1650

Return On Assets Statistics
High	Average	Low
16.13 %	-5.22 %	-39.25 %
(Jun 30 2021)		(Mar 31 2017)

Financial Statements
Collegium Pharmaceutical Inc 's Assets	$ 2,116 million	COLL's Balance sheet
Collegium Pharmaceutical Inc 's Income	$ -15 million	Quarterly COLL's Income Statement
COLL's Income by Division		See COLL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-0.15 %	45.53 %	-2.65 %	70.41 %	7.67 %
Total Assets in million	1,657	1,659	1,140	1,171	687
Y / Y Net Income Change	-9.13 %	43.68 %	-	-	167.33 %
Net Income in million	63	69	48	-25	72
Annual Return On Assets	3.79 %	4.17 %	4.22 %	-2.13 %	10.41 %

COLL's 5 Years Annual ROA >> Back to COLL Management Effectiveness >> Compare COLL ROA to its Competitors

Comment on COLL's ROA in the fiscal year ending 2025

In the fiscal year 2025 Collegium Pharmaceutical Inc 's ROA decreased compared to previous year to 3.79 %, due to deterioration of net income -9.13 % to $62.87 million, from $69.19 million a year ago, as COLL's assets were $1,656.83 million.

More Return On Assets Ratios
COLL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
COLL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for COLL's Competitors
Subscribers only: Roa for Collegium Pharmaceutical Inc 's Suppliers
Subscribers only: Return On Assets for COLL's Customers

You may also want to know
COLL's Roi	COLL's Inventory Turnover Ratio	COLL's Growth Rates	COLL's Dividend Comparisons
	COLL's Profitability Ratios	COLL's Asset Turnover Ratio	COLL's Dividend Growth
COLL's Roe	COLL's Valuation Ratios	COLL's Financial Strength Ratios	COLL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Viemed Healthcare Inc	7.49 %
Edwards Lifesciences Corporation	7.41 %
Ani Pharmaceuticals Inc	7.40 %
Addus Homecare Corp	7.32 %
Livanova Plc	7.31 %
Pacific Health Care Organization Inc	7.17 %
Nature s Sunshine Products inc	7.14 %
Bio techne Corp	7.12 %
Concentra Group Holdings Parent Inc	7.09 %
Phibro Animal Health Corporation	7.01 %
Ensign Group Inc	6.88 %
Royalty Pharma Plc	6.87 %
Davita Inc	6.77 %
Quest Diagnostics Inc	6.74 %
Align Technology inc	6.56 %
Corcept Therapeutics Inc	6.45 %
Brightspring Health Services Inc	5.93 %
Amneal Pharmaceuticals Inc	5.90 %
Siga Technologies Inc	5.73 %
Medtronic Plc	5.71 %
Labcorp Holdings Inc	5.40 %
Merit Medical Systems Inc	5.34 %
Sotera Health Company	5.03 %
Vericel Corporation	5.02 %
Kewaunee Scientific Corporation	4.96 %
Pacs Group Inc	4.78 %
Amphastar Pharmaceuticals Inc	4.70 %
Abbvie Inc	4.68 %
The Cooper Companies Inc	4.57 %
IMPACT BIOMEDICAL INC.	4.47 %

Date modified: 2026-09-08T17:12:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.